Clinical trial
The Efficacy of a Lock Solution Containing Taurolidine, Citrate and Heparin for the Prevention of Tunneled Central Line-associated Bloodstream Infections in Pediatric Oncology Patients, a Randomized Controlled, Mono-center Trial.
NCT05740150 is registered in ClinicalTrials.gov with Princess Maxima Center for Pediatric Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy of a Lock Solution Containing Taurolidine, Citrate and Heparin for the Prevention of Tunneled Central Line-associated Bloodstream Infections in Pediatric Oncology Patients, a Randomized Controlled, Mono-center Trial.
- Lead sponsor
- Princess Maxima Center for Pediatric Oncology
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- October 27, 2020
- Completion date
- December 1, 2023
- Enrollment
- 462 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
central line-associated bloodstream infection (clabsi)